Your session is about to expire
← Back to Search
Inqovi Maintenance Therapy for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Study Summary
This trial is being done to see if Inqovi is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after stem cell transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 14 Patients • NCT04055844Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am scheduled for my first stem cell transplant from a donor.I do not have any untreated infections.My bone marrow transplant donor matches me closely.I am able to care for myself and perform daily activities.I have an active hepatitis B or C infection.I do not have severe heart failure or a history of poor heart function.I have had a stem cell transplant from a donor.My latest bone marrow test shows less than 5% myeloblasts.My transplant will use a milder preparation method.I have been diagnosed with MDS or CMML.I've been cancer-free for over a year, or I only had skin/cervical cancer.I have a condition that affects my ability to swallow or absorb pills.I am 18 years old or older.I have or had serious heart rhythm problems or long-QT syndrome.
- Group 1: Recommended Phase 2 Dose Expansion (RP2S) Inqovi
- Group 2: Dose Escalation Inqovi
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what particular purposes is Inqovi typically prescribed?
"Inqovi is the indicated prescription for intermediate-2 IPSS risk category, however it may also be prescribed to address refractory anemias and high-risk ipss as well."
What is the scope of participation in this research endeavor?
"Affirmative, the information accessible on clinicaltrials.gov attests to this trial's current recruitment status. It was initially posted on September 17th 2021 and underwent its last update two weeks later; a total of 22 participants are sought from 2 centres."
Are there any vacancies remaining on this research?
"Affirmative. Clinicaltrials.gov reports that this research study is currently accepting participants and was first published on September 17th 2021 before being amended two weeks later. At present, the project requires 22 individuals to be recruited from 2 distinct medical centres."
Have any other experiments been conducted with Inqovi?
"Currently, there are 104 trials for Inqovi in progress; 16 of which are Phase 3. Most notably, the vast majority of these studies originate from Philadelphia but across 1491 locations globally clinical trials with Inqovi is also taking place."
Are there known risks of using Inqovi?
"Due to the limited amount of data available for Inqovi, our team has given it a score of 1 on a scale from 1 to 3 in terms of safety. This is because this is an early-stage trial with little information about its efficacy and safety."
Share this study with friends
Copy Link
Messenger